Chelsea E Gottlieb1, Anne M Mills2, Janet V Cross3, Kari L Ring4. 1. Department of Pathology, University of Virginia Health System, PO Box 800712, Charlottesville, VA, United States. Electronic address: CEG2KC@hscmail.mcc.virginia.edu. 2. Department of Pathology, University of Virginia Health System, PO Box 800712, Charlottesville, VA, United States. Electronic address: AMM7R@hscmail.mcc.virginia.edu. 3. Department of Pathology, University of Virginia Health System, PO Box 800712, Charlottesville, VA, United States. Electronic address: jvc5b@eservices.virginia.edu. 4. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health System, PO Box 800712, Charlottesville, VA, United States. Electronic address: kel7j@hscmail.mcc.virginia.edu.
Abstract
OBJECTIVE: Data on PD-L1 expression in high grade serous ovarian carcinoma (HGSOC) is mixed. Some studies report robust tumor staining and others identify expression limited to tumor-associated macrophages (TAM). TAM PD-L1 expression is induced in HGSOC metastatic implants from patients who have undergone chemotherapy. However, it is unclear whether TAM acquisition of PD-L1 plays a role in treatment naïve tumors. We investigated PD-L1 expression in primary ovarian tumors and matched metastatic implants from predominantly treatment-naïve HGSOC. METHODS: Sixty one primary HGSOC were evaluated with PD-L1 and CD68 IHC: 40 on TMA and 21 on whole section. Whole section cases were matched to a metastatic implant. TAM were delineated by CD68. Membranous PD-L1 staining was scored separately for tumor cells and TAM. RESULTS: Eight percent of primary HGSOC demonstrated PD-L1 expression. In contrast, 74% showed PD-L1+ TAM. In the 16 treatment naïve cases, 13 (81.3%) demonstrated fidelity in intratumoral PD-L1 expression between the primary and metastatic site. Of the 21 matched pairs, only one case (4.8%) did not exhibit PD-L1 positive TAM in the metastatic implant and 19 (90.5%) showed fidelity across both locations. Intratumoral and immune infiltrate PD-L1 expression was not different in cases who received neoadjuvant chemotherapy compared to treatment naïve cases. CONCLUSIONS: PD-L1+ TAM are common in both primary and metastatic HGSOC however tumoral PD-L1 staining is rare. There was high fidelity of PD-L1 expression when comparing primary tumors and metastatic implants in treatment naïve specimens. Clinical trials are needed to determine whether tumor-associated staining correlates with clinical response to PD-1/PD-L1 inhibition. Copyright Â
OBJECTIVE: Data on PD-L1 expression in high grade serous ovarian carcinoma (HGSOC) is mixed. Some studies report robust tumor staining and others identify expression limited to tumor-associated macrophages (TAM). TAMPD-L1 expression is induced in HGSOC metastatic implants from patients who have undergone chemotherapy. However, it is unclear whether TAM acquisition of PD-L1 plays a role in treatment naïve tumors. We investigated PD-L1 expression in primary ovarian tumors and matched metastatic implants from predominantly treatment-naïve HGSOC. METHODS: Sixty one primary HGSOC were evaluated with PD-L1 and CD68 IHC: 40 on TMA and 21 on whole section. Whole section cases were matched to a metastatic implant. TAM were delineated by CD68. Membranous PD-L1 staining was scored separately for tumor cells and TAM. RESULTS: Eight percent of primary HGSOC demonstrated PD-L1 expression. In contrast, 74% showed PD-L1+ TAM. In the 16 treatment naïve cases, 13 (81.3%) demonstrated fidelity in intratumoral PD-L1 expression between the primary and metastatic site. Of the 21 matched pairs, only one case (4.8%) did not exhibit PD-L1 positive TAM in the metastatic implant and 19 (90.5%) showed fidelity across both locations. Intratumoral and immune infiltrate PD-L1 expression was not different in cases who received neoadjuvant chemotherapy compared to treatment naïve cases. CONCLUSIONS:PD-L1+ TAM are common in both primary and metastatic HGSOC however tumoral PD-L1 staining is rare. There was high fidelity of PD-L1 expression when comparing primary tumors and metastatic implants in treatment naïve specimens. Clinical trials are needed to determine whether tumor-associated staining correlates with clinical response to PD-1/PD-L1 inhibition. Copyright Â
Authors: Hye-Yeong Kim; Ran Li; Thomas S C Ng; Gabriel Courties; Christopher Blake Rodell; Mark Prytyskach; Rainer H Kohler; Mikael J Pittet; Matthias Nahrendorf; Ralph Weissleder; Miles A Miller Journal: ACS Nano Date: 2018-12-11 Impact factor: 15.881
Authors: Anne M Mills; Lauren C Peres; Alice Meiss; Kari L Ring; Susan C Modesitt; Sarah E Abbott; Anthony J Alberg; Elisa V Bandera; Jill Barnholtz-Sloan; Melissa L Bondy; Michele L Cote; Ellen Funkhouser; Patricia G Moorman; Edward S Peters; Ann G Schwartz; Paul D Terry; Kristin Wallace; Joellen M Schildkraut Journal: Int J Gynecol Pathol Date: 2019-03 Impact factor: 2.762
Authors: Fei Xing; Yin Liu; Shih-Ying Wu; Kerui Wu; Sambad Sharma; Yin-Yuan Mo; Jiamei Feng; Stephanie Sanders; Guangxu Jin; Ravi Singh; Pierre-Alexandre Vidi; Abhishek Tyagi; Michael D Chan; Jimmy Ruiz; Waldemar Debinski; Boris C Pasche; Hui-Wen Lo; Linda J Metheny-Barlow; Ralph B D'Agostino; Kounosuke Watabe Journal: Cancer Res Date: 2018-07-19 Impact factor: 12.701